G-protein-coupled receptor regulators and methods of use thereof
US-2024417378-A1 · Dec 19, 2024 · US
Fused tricyclic compounds useful as anticancer agents
US12410187B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12410187-B2 |
| Application number | US-202017436137-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2020 |
| Priority date | Mar 5, 2019 |
| Publication date | Sep 9, 2025 |
| Grant date | Sep 9, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, that is 1-[(12aR)-9-(2-chloro-6-hydroxyphenyl)-10-fluoro-8-(prop-1-yn-1-yl)-3,4,12,12a-tetrahydro-6H-pyrazino[2,1-c][1,4]benzoxazepin-2 (1H)-yl]prop-2-en-1-one, 2. A compound that is 1-[(12aR)-9-(2-chloro-6-hydroxyphenyl)-10-fluoro-8-(prop-1-yn-1-yl)-3,4,12,12a-tetrahydro-6H-pyrazino[2,1-c][1,4]benzoxazepin-2 (1H)-yl]prop-2-en-1-one, 3. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable excipient. 4. The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is the rotational isomer 1 5. The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is the rotational isomer 2
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
Ortho-condensed systems · CPC title
Antineoplastic agents · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12410187B2 cover?
- The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
- Who is the assignee on this patent?
- Astrazeneca Ab
- What technology area does this patent fall under?
- Primary CPC classification C07D498/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).